Amgen Europe – Impact analysis of the less frequent dosing of Erythropoiesis Stimulating Agents in patients on chronic haemodialysis

Amgen is an authorative biotechnology company. The advantage of their medicine Aranesp® - an Erythropoiesis Stimulatinge Agent (ESA), used for the treatment of anaemia with chronic kidney patients for instance - is that it needs to be administrated less frequently than other ESA's.

Description | business case

The goal of the study (‘Mercurius study') was to map the quantitative and qualitative impact of the less frequent dosing of ESA's in chronic kidney patients on haemodialysis. hict performed this impact analysis in 40 dialysis centres over 9 European countries. The Mercurius study was later on expanded to the Canadian market.

Approach

For the analysis an impact model was developed existing of a conceptual model, a generic model and a hospital-specific model:

  • The conceptual model describes the three dimensions of this impact analysis: organisation, processes and activities.
  • The generic model contains the basics for research and describes the standard processes, activities and functions involved in the flow of an ESA injection throughout the hospital.
  • The entire flow of the ESA injection was followed through every individual hospital and hospital-specific data were collected to result in hospital-specific models.

A calculation model was also developed in order to calculate the impact of the less frequent dosing of ESA's on the costs of the individial hospitals. The qualitative impact was defined by means of structured interviews and observations in the hospitals.

Result

  • global confirmation of the significant cost savings because of the less frequent dosing of ESA;
  • definition of the qualitative advantages for each participating hospital;
  • publication of these results in international journals (e.g. Journal of Medical Economics) and on international and national conferences (e.g. ASN, ERA-EDTA, ESCP, SSN, etc.);
  • strengthening of the commercial position of Aranesp® in the participating hospitals;
  • recommendations, best practices and benchmarks for the participating hospitals;
  • development of a solid partnership between Amgen and the participating hospitals.

Your contact person

Ann Tanghe
By submitting this form, you accept the Mollom privacy policy.
Ezelstraat 69 | B- 8000 Brugge | Belgium | Phone: +32.50.33.33.40 | Fax: +32.50.33.33.39 | BTW BE 0866 039 556 | RPR/RPM Brugge | e-mail: info@hict.com